Delivery Order SPE2DB20D2104-SPE2DB25FMUML
- Not listed
- The Defense Logistics Agency awarded a delivery order valued at $5,707.30 to AmerisourceBergen Drug Corp for Repatha 140 mg/ml SureClick auto-injectors, with performance at the contractor's Conshohocken, Pennsylvania facility. This firm fixed-price, competitively awarded delivery order is scheduled for completion by August 28, 2025, and represents a non-set-aside procurement. AmerisourceBergen Drug Corp, a major pharmaceutical distributor and critical federal medical supply vendor, fulfills this...
- The Defense Logistics Agency awarded a delivery order valued at $1,388.56 to AmerisourceBergen Drug Corp for Repatha 140 mg/mL SureClick auto-injectors, with an ultimate completion date of July 29, 2025. This competitively awarded, firm fixed-price contract carries no set-aside designation and specifies performance at the vendor's Conshohocken, Pennsylvania location. The delivery order is issued under AmerisourceBergen Drug Corp's larger Indefinite Delivery Contract (IDC) with DLA Troop...
- The Defense Logistics Agency awarded a delivery order valued at $20,781.90 to AmerisourceBergen Drug Corp for Repatha 140 mg/ml SureClick auto-injectors, with a completion date of June 26, 2025. This non-set-aside, competitively awarded contract utilizes firm fixed pricing and is performed at the contractor's corporate office location in Conshohocken, Pennsylvania. The delivery order falls under AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with DLA Troop Support Medical,...
- The Defense Logistics Agency awarded a delivery order valued at $4,761.42 to AmerisourceBergen Drug Corp for Repatha 140 mg/ml SureClick auto-injectors, with an ultimate completion date of September 8, 2025. This is a firm fixed price, competitively awarded delivery order with no set-aside designation. The place of performance is AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. This delivery order is issued under AmerisourceBergen's larger Indefinite Delivery Contract...
- The Defense Logistics Agency awarded a delivery order valued at $2,603.55 to AmerisourceBergen Drug Corp for Repatha 140 mg/ml SureClick auto-injectors, with performance completed by August 13, 2025. This non-set-aside contract reflects a firm fixed-price delivery order issued under competitive procedures. AmerisourceBergen Drug Corp, a major pharmaceutical distributor headquartered in Conshohocken, Pennsylvania, serves as a critical vendor for federal medical procurement, particularly...
- The Defense Logistics Agency (DLA) awarded a delivery order valued at $34,507.05 to AmerisourceBergen Drug Corp for Repatha 140 mg/mL SureClick auto-injectors, with an ultimate completion date of September 3, 2025. This competitively awarded, firm fixed-price delivery order was issued under a non-set-aside procurement and represents a single transaction for pharmaceutical supply to support federal medical needs. The place of performance is AmerisourceBergen's corporate office in Conshohocken,...
- The Defense Logistics Agency awarded a $27,040.46 delivery order to AmerisourceBergen Drug Corp for Repatha 140 mg/mL SureClick auto-injectors, with a completion date of September 3, 2025. This competitively awarded, firm fixed-price contract contains no set-aside designation and is being performed at the contractor's corporate office location in Conshohocken, Pennsylvania. The delivery order is issued under AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with DLA Troop Support...
- The Defense Logistics Agency awarded a delivery order valued at $1,203.06 to AmerisourceBergen Drug Corp for Repatha 140 mg/ml SureClick auto-injectors. This firm fixed-price contract, issued on August 27, 2025, with an ultimate completion date of August 28, 2025, represents a child delivery order under AmerisourceBergen's larger Indefinite Delivery Contract with DLA Troop Support Medical. The award was competitively awarded with no set-aside designation, and performance will occur at...
- The Defense Logistics Agency awarded a delivery order valued at $1,238.46 to AmerisourceBergen Drug Corp for Repatha 140 mg/ml SureClick auto-injectors, with an ultimate completion date of July 14, 2025. This firm fixed price, competitively awarded contract was issued without a set-aside designation and is being fulfilled from the vendor's place of business in Conshohocken, Pennsylvania. The delivery order represents a child contract under AmerisourceBergen's larger Indefinite Delivery...
- The Defense Logistics Agency awarded a delivery order valued at $1,041.42 to AmerisourceBergen Drug Corp for Repatha 140 mg/ml SureClick auto-injectors, with a completion date of July 23, 2025. This non-competitive, firm fixed-price delivery order was issued on July 22, 2025, and will be performed at AmerisourceBergen's corporate headquarters in Conshohocken, Pennsylvania. Repatha is a prescription medication used to treat high cholesterol and reduce the risk of cardiovascular disease. This...
- SPE2DB20D2104Indefinite Delivery Contract
- SPE2DB20D2104-SPE2DB25FMUMLDelivery Order
The Defense Logistics Agency awarded a delivery order valued at $1,562.13 to AmerisourceBergen Drug Corp for Repatha 140 mg/ml SureClick auto-injectors, with performance in Conshohocken, Pennsylvania and completion by July 2, 2025. This is a firm fixed price delivery order issued under a competitive process with no set-aside designation. AmerisourceBergen Drug Corp, a major pharmaceutical distributor headquartered in Pennsylvania, serves as a critical vendor for federal medical procurement, particularly supporting military and veteran healthcare systems through the Defense Logistics Agency's Medical Supply Chain. This delivery order is issued under AmerisourceBergen Drug Corp's substantial Indefinite Delivery Contract (IDC) with DLA Troop Support Medical (SPE2DX), valued at $999,999,999.00 and extending through December 2026. The parent IDC functions as a comprehensive global pharmaceutical support vehicle enabling the company to supply a broad range of pharmaceutical products and medical supplies to support military healthcare programs worldwide. Repatha (evolocumab) is a PCSK9 inhibitor used for cholesterol management, reflecting the breadth of specialty medications available through this contract vehicle to support Defense Health Agency operations and other federal healthcare systems.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | Not listed | $1.6k | 7/1/25 |